MX2021002818A - Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k). - Google Patents

Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).

Info

Publication number
MX2021002818A
MX2021002818A MX2021002818A MX2021002818A MX2021002818A MX 2021002818 A MX2021002818 A MX 2021002818A MX 2021002818 A MX2021002818 A MX 2021002818A MX 2021002818 A MX2021002818 A MX 2021002818A MX 2021002818 A MX2021002818 A MX 2021002818A
Authority
MX
Mexico
Prior art keywords
ube2k
methods
conjugating enzyme
treating cancer
ubiquitin conjugating
Prior art date
Application number
MX2021002818A
Other languages
English (en)
Inventor
Vivek K Vishnudas
Stephane Gesta
Anne R Diers
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of MX2021002818A publication Critical patent/MX2021002818A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La descripción proporciona métodos para el tratamiento del cáncer en un sujeto que comprenden administrar al sujeto un inhibidor de la enzima conjugadora de ubiquitina E2 K (UBE2K). El inhibidor de UBE2K puede administrarse al sujeto como monoterapia o en combinación con un agente adicional, tal como un agente contra el cáncer.
MX2021002818A 2018-09-10 2019-09-10 Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k). MX2021002818A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862729348P 2018-09-10 2018-09-10
PCT/US2019/050465 WO2020055906A1 (en) 2018-09-10 2019-09-10 Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k)

Publications (1)

Publication Number Publication Date
MX2021002818A true MX2021002818A (es) 2021-07-15

Family

ID=69778426

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002818A MX2021002818A (es) 2018-09-10 2019-09-10 Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).

Country Status (13)

Country Link
US (1) US20210252036A1 (es)
EP (1) EP3849543A4 (es)
JP (1) JP2022500378A (es)
KR (1) KR20210057121A (es)
CN (1) CN112996504A (es)
AU (1) AU2019339896A1 (es)
BR (1) BR112021004417A2 (es)
CA (1) CA3112191A1 (es)
IL (1) IL281327A (es)
MA (1) MA53623A (es)
MX (1) MX2021002818A (es)
SG (1) SG11202102417TA (es)
WO (1) WO2020055906A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11091447B2 (en) * 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use
CA3238430A1 (en) * 2021-11-17 2023-05-25 Berg Llc Compounds for use in treating gastric cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1784646B1 (en) * 2004-08-11 2012-06-13 Albert Einstein College Of Medicine Of Yeshiva University Method for identifying metastasis in motile cells
CN101583622B (zh) * 2006-11-02 2012-11-07 舒泰神（北京）生物制药股份有限公司 用于破坏与泛素化相关的酶的相互作用的抑制剂和其应用
KR100919832B1 (ko) * 2009-05-15 2009-10-01 고려대학교 산학협력단 Ｈｉｐ―２ 유전자 발현을 억제하여 암세포의 방사선에 대한 민감도를 증진하는 방법
WO2014094138A1 (en) * 2012-12-21 2014-06-26 Universite De Montreal Screening methods to identify compounds inhibiting the activity of e2 enzymes by stabilization of non-covalent ubiquitin-e2 complexes and pharmaceutical applications related to e2 inhibitors
KR101525122B1 (ko) * 2013-08-05 2015-06-03 광주과학기술원 Ｕｂｂ 넉­다운에 의한 암의 예방 또는 치료
CN106132436B (zh) * 2014-02-21 2021-06-15 Ibc药品公司 通过诱导对trop-2表达细胞的免疫应答的疾病疗法

Also Published As

Publication number Publication date
US20210252036A1 (en) 2021-08-19
BR112021004417A2 (pt) 2021-06-01
SG11202102417TA (en) 2021-04-29
CN112996504A (zh) 2021-06-18
IL281327A (en) 2021-04-29
WO2020055906A1 (en) 2020-03-19
KR20210057121A (ko) 2021-05-20
EP3849543A4 (en) 2022-11-30
AU2019339896A1 (en) 2021-04-08
WO2020055906A8 (en) 2021-01-07
MA53623A (fr) 2021-07-21
JP2022500378A (ja) 2022-01-04
EP3849543A1 (en) 2021-07-21
CA3112191A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2019011431A (es) Inhibidores de proteina 1 de muerte celular programada (pd-1)/ligando 1 de muerte programada (pd-l1).
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
ZA201906269B (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
EP4140487A8 (en) Combination therapy for treating cancer
MX2019012464A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
MX2017015896A (es) Agente anticancerigeno.
EA201492187A1 (ru) Способы лечения солидных опухолей с использованием кофермента q10
MX2019013862A (es) Terapia de combinacion.
WO2018208954A3 (en) Peptidomimetic macrocycles and uses thereof
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2017011018A (es) Inhibicion de la actividad de olig2.
ZA201901367B (en) Inhibition of olig2 activity
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.